RESPIRATORY SYNCYTIAL VIRUS (RSV)
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS (RSV) explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS (RSV) trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Pregnant RSV shot shields infants: new aussie study
⭐️ VACCINE ⭐️ OngoingThis study looks at how well the RSV vaccine (ABRYSVO) given during pregnancy prevents serious RSV lung infections in babies. Researchers will review health records of infants up to 12 months old who were hospitalized with breathing problems. They will compare RSV test results to…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 17, 2026 04:36 UTC
-
Pregnant Women's RSV shot shields newborns, Real-World study shows
⭐️ VACCINE ⭐️ OngoingThis study checks how well the ABRYSVO vaccine works when given to pregnant people to protect their babies from RSV, a serious lung infection. Researchers will compare health records of nearly 40,000 infants born to vaccinated versus unvaccinated mothers. The goal is to see if th…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Sponsor: Pfizer • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:06 UTC
-
New mRNA vaccine aims to shield against RSV
⭐️ VACCINE ⭐️ OngoingThis early-stage study tests a new mRNA vaccine called JCXH-108 to see if it is safe and triggers an immune response against RSV, a common respiratory virus. About 75 healthy adults aged 18-45 and 60 or older will receive either the vaccine or a placebo. The main goals are to che…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE1 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 14, 2026 12:03 UTC
-
Scientists dive deep into RSV vaccine immune response
Knowledge-focused OngoingThis study looks at how the immune system of adults aged 60 and older responds to an approved RSV vaccine. Researchers will measure antibodies and track side effects for 6 months after vaccination. The goal is to learn more about how the vaccine protects people and find early sig…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS (RSV)
Phase: PHASE4 • Sponsor: Emory University • Aim: Knowledge-focused
Last updated May 17, 2026 04:32 UTC